TLR4 and cancer: As an activator of the cancer-immunity cycle, high mobility group box 1 is released simultaneously with cancer antigens to act on TLR2 and TLR4 of DCs to promote DC maturation and induce antitumor immune responses when cancer cells cause immunogenic cell death [59].